Healthcare provider profile · identity verified

Jennifer Lyn Bard, MD

Family Practice · LONGVIEW, WA · NPI 1346348596

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	535	169
Losartan Potassium	Losartan Potassium	438	136
Lisinopril	Lisinopril	417	132
Levothyroxine Sodium	Levothyroxine Sodium	355	94
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	329	61
Amlodipine Besylate	Amlodipine Besylate	315	98
Simvastatin	Simvastatin	269	78
Metoprolol Tartrate	Metoprolol Tartrate	210	70
Gabapentin	Gabapentin	208	61
Albuterol Sulfate Hfa	Albuterol Sulfate	189	73
Potassium Chloride	Potassium Chloride	181	55
Furosemide	Furosemide	170	56
Pantoprazole Sodium	Pantoprazole Sodium	157	57
Metformin Hcl	Metformin Hcl	154	45
Oxycodone Hcl	Oxycodone Hcl	150	29
Trazodone Hcl	Trazodone Hcl	137	49
Atenolol	Atenolol	128	39
Spironolactone	Spironolactone	123	41
Glipizide	Glipizide	122	41
Tramadol Hcl	Tramadol Hcl	122	27
Pradaxa	Dabigatran Etexilate Mesylate	120	41
Hydrochlorothiazide	Hydrochlorothiazide	112	35
Metoprolol Succinate	Metoprolol Succinate	112	38
Rosuvastatin Calcium	Rosuvastatin Calcium	108	35
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	107	16
Metformin Hcl Er	Metformin Hcl	106	37
Duloxetine Hcl	Duloxetine Hcl	101	31
Sertraline Hcl	Sertraline Hcl	99	32
Allopurinol	Allopurinol	94	27
Prednisone	Prednisone	87	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	85	28
Jardiance	Empagliflozin	78	26
Tamsulosin Hcl	Tamsulosin Hcl	72	28
Bupropion Xl	Bupropion Hcl	65	20
Alendronate Sodium	Alendronate Sodium	61	24
Humulin N	Insulin Nph Human Isophane	59	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	55	17
Pravastatin Sodium	Pravastatin Sodium	54	18
Buspirone Hcl	Buspirone Hcl	52	14
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	50	17
Propranolol Hcl	Propranolol Hcl	49	14
Eliquis	Apixaban	48	suppressed
Mirtazapine	Mirtazapine	48	16
Triamcinolone Acetonide	Triamcinolone Acetonide	44	36
Venlafaxine Hcl Er	Venlafaxine Hcl	44	14
Famotidine	Famotidine	43	15
Meloxicam	Meloxicam	43	15
Azelastine Hcl	Azelastine Hcl	42	15
Bupropion Hcl Sr	Bupropion Hcl	42	16
Warfarin Sodium	Warfarin Sodium	42	17
Omeprazole	Omeprazole	40	17
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	40	14
Citalopram Hbr	Citalopram Hydrobromide	38	12
Escitalopram Oxalate	Escitalopram Oxalate	38	11
Alvesco	Ciclesonide	37	15
Estradiol	Estradiol	37	21
Fluoxetine Hcl	Fluoxetine Hcl	36	15
Ondansetron Odt	Ondansetron	35	suppressed
Ozempic	Semaglutide	35	suppressed
Pregabalin	Pregabalin	34	13
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	34	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	13
Lorazepam	Lorazepam	32	13
Carvedilol	Carvedilol	31	12
Humulin R	Insulin Regular, Human	31	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	31	13
Wixela Inhub	Fluticasone Propion/Salmeterol	31	14
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	11
Alprazolam	Alprazolam	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	25	21
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	11
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	24	suppressed
Methocarbamol	Methocarbamol	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Amoxicillin	Amoxicillin	23	12
Finasteride	Finasteride	23	suppressed
Torsemide	Torsemide	23	11
Chlorthalidone	Chlorthalidone	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Topiramate	Topiramate	21	suppressed
Nystatin	Nystatin	20	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Azithromycin	Azithromycin	17	14
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Ketoconazole	Ketoconazole	16	11
Montelukast Sodium	Montelukast Sodium	16	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	14	14
Cephalexin	Cephalexin	14	suppressed
Cholestyramine	Cholestyramine (With Sugar)	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Naproxen	Naproxen	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error